Faeth Therapeutics (FTH) Free Cash Flow by Year
Faeth Therapeutics, Inc. recorded an outflow of $20.5M in free cash flow in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to an outflow of $43.3M in free cash flow. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Faeth Therapeutics, Inc. has filed alongside them.
Ticker history: SNSE became FTH (Faeth Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View SNSE history.
Annual figures, oldest first. Point at a bar to read its period.
FTH Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
FTH Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Faeth Therapeutics, Inc. financials
Frequently Asked Questions
Faeth Therapeutics, Inc. recorded an outflow of $20.5M in free cash flow in fiscal year 2025.
Faeth Therapeutics, Inc. (FTH) reported an outflow of $24.8M in free cash flow in fiscal year 2024 and an outflow of $20.5M in free cash flow in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Faeth Therapeutics, Inc. (FTH) reported an outflow of $43.3M in free cash flow over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 6 fiscal years this page covers, Faeth Therapeutics, Inc. (FTH) free cash flow went from -$18.9M in fiscal year 2020 to -$20.5M in fiscal year 2025.
Faeth Therapeutics, Inc. (FTH) reported -$13.0M in free cash flow in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Faeth Therapeutics, Inc. (FTH) reported on that line in every period on record.